Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» neurofibromatosis
neurofibromatosis
AstraZeneca, Merck secure FDA nod for Koselugo to treat paediatric patients with NF1 genetic disorder
Pharmaceutical Business Review
Mon, 04/13/20 - 10:46 am
AstraZeneca
Merck
FDA
Koselugo
pediatric
neurofibromatosis
AstraZeneca, Merck win quick OK for a rare disease drug — as the FDA declares it can still move fast during a crippling pandemic
Endpoints
Sat, 04/11/20 - 11:05 pm
AstraZenca
Merck
FDA
selumetinib
neurofibromatosis
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
CP Wire
Fri, 08/3/18 - 09:25 am
AstraZeneca
Merck
selumetinib
Array Biopharma
orphan drugs
NF1
neurofibromatosis